Davis Polk is advising Deutsche Inversiones Limitada as financial adviser to CFR Pharmaceuticals in connection with its approximately $2.9 billion acquisition by Abbott Laboratories. The transaction is expected to close by the end of the third quarter of 2014.

CFR Pharmaceuticals, headquartered in Santiago, Chile, participates in 15 Latin American markets and currently markets more than 1,000 products. Abbott is a global health care company devoted to improving life through the development of products and technologies that span the breadth of health care.

The Davis Polk team includes partners Phillip R. Mills and Manuel Garciadiaz and associate Boyoon Choi. Members of the Davis Polk team are based in the New York and São Paulo offices.